HOUSTON / Oct 07, 2025 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) congratulates our long-standing scientific advisor, Dr. Shimon Sakaguchi, on being awarded the Nobel Prize for his pioneering discovery of regulatory T cells (Tregs) which protect the body from autoimmune diseases. This discovery has reshaped modern immunology and opened new therapeutic frontiers. Dr. Sakaguchi has served as a scientific advisor... Read More

Following the positive interim results in 5 patients announced earlier this year, a total of 9 patients have been enrolled as planned The study is progressing according to protocol, and no safety issues have been reported Study completion is anticipated in Q4 2025 with topline to follow HOUSTON , Sept. 29, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology... Read More

The ALSTARS Trial is a well powered randomized, multi-center, double-blind, placebo-controlled, 24-week study of COYA 302 in people with Amyotrophic Lateral Sclerosis (ALS) Patients completing the initial 24-week treatment will be invited to participate in a 24-week blinded extension period, during which all participants will receive COYA 302 The ALSTARS Trial will enroll 120 ALS participants at approximately 25 centers in... Read More

COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by chronic and sustained inflammation; COYA 303 demonstrated significant attenuation of neuroinflammation in cortex and hippocampus brain regions and upregulation of anti-inflammatory markers, and significant improvement of... Read More

NEALS, the world's largest ALS research consortium, has selected the COYA 302 trial and it is now affiliated with NEALS as part of its mission to accelerate the development of new treatments for people living with ALS; Following FDA's recent acceptance of the COYA 302 IND, Coya plans to initiate its Phase 2 study in people with ALS in Q4 2025; The COYA 302 study will be presented during the NEALS Educational Webinar on... Read More

HOUSTON , Sept. 3, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming investor conferences this month. H.C. Wainwright 27th Annual Global Investment... Read More

FDA acceptance enables initiation of a Phase 2 multicenter, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of COYA 302 in patients with ALS HOUSTON , Aug. 25, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with... Read More

HOUSTON , Aug. 12, 2025 /PRNewswire/ -- Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended June 30, 2025 . Recent Corporate Highlights Submitted to FDA on June 30,... Read More

Study demonstrates a correlation between peripheral pro-inflammatory mechanisms, particularly monocytes and oxidative stress, in the progression and severity of Parkinson’s Disease (PD); In addition to PD, Coya has sponsored research demonstrating the potentially critical role of inflammation in the progression and severity of other diseases, such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and... Read More

HOUSTON / Jul 22, 2025 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the management team will participate in the BTIG Virtual Biotechnology Conference on July 29 – 30, 2025. For more information about the BTIG Virtual Biotechnology Conference, or to register... Read More

HOUSTON / Jun 18, 2025 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the iAccess Alpha Virtual Best Ideas Summer Conference on Tuesday, June 24, 2025. Event: iAccess Alpha Virtual Best Ideas... Read More

Patent protection strengthens Coya’s strategic and business development optionality Coya and its partners are continuing to broaden and expand its rh IL-2 and rh IL-2 combination patent portfolio with ongoing filings and prosecutions Coya is on track and plans to submit the IND for COYA 302 (a proprietary combination of the low dose-rhIL-2 + CTLA4-Ig) by the end of June supporting the initiation of the Phase 2b study in... Read More

HOUSTON / May 16, 2025 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in the H.C. Wainwright 3 rd Annual BioConnect Conference being held in New York City on Tuesday, May 20, 2025. Chief Executive Officer Arun Swaminathan, Ph.D. will... Read More

HOUSTON / May 13, 2025 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025. Recent Corporate Highlights Announced positive interim results of an investigator-initiated proof of... Read More

HOUSTON / May 08, 2025 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in two upcoming conferences in May 2025. Chief Executive Officer Arun Swaminathan, Ph.D. and Chief Financial Officer David Snyder will be available for one-on-one meetings... Read More

Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in the number and suppressive function of Tregs compared to baseline values. Clinically, patients with Frontotemporal Dementia (FTD) demonstrated minimal to no cognitive decline throughout the study period. Treatment was well... Read More

COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory therapeutic in autoimmune and neurodegenerative diseases COYA 303 produced a statistically significantly higher Treg suppressive effect on pro-inflammatory myeloid cells and enhanced Treg survival in in vitro human immune cells,... Read More

Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated “Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer’s disease” HOUSTON / Apr 01, 2025 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg)... Read More

Regulatory T cell-derived exosomes (Treg exosomes) have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as previously published here Treg exosomes are end-stage differentiated, making them less likely to be affected by pro-inflammatory factors that may impact their suppressive function The work planned includes GMP processes and... Read More

HOUSTON / Mar 18, 2025 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers... Read More

HOUSTON / Feb 25, 2025 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Dr. Stanley H. Appel, Professor of Neurology, Houston Methodist Hospital will participate in a BTIG hosted KOL webcast “Is Alzheimer’s next... Read More

Investigator-initiated data from Houston Methodist Hospital showed LD IL-2 reduced proinflammatory factors, both systemically and within the central nervous system, while demonstrating statistically significant improvement in beta amyloid 42 clearance with stabilization of cognitive decline over a five-month treatment period Comprehensive data set will be presented and released throughout 2025 and in a peer reviewed... Read More

HOUSTON / Feb 04, 2025 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference being held February 11-12, 2025 in a virtual format. Event:... Read More

Preclinical study anticipated to be published in 1H 2025 documenting combination’s additive and/or synergistic anti-inflammatory signal; Company will seek to advance asset in neurodegenerative and autoimmune diseases through the next stages alongside a strategic partner HOUSTON / Jan 21, 2025 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing... Read More

This open-label Phase 1 study measures safety, peripheral and central inflammation, effects on Treg cell populations, and FTD progression; Five of the 8 planned FTD subjects have been enrolled to date; Results of study will inform Coya’s randomized, double-blinded Phase 2 trial of COYA 302 in patients with FTD HOUSTON / Dec 18, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a... Read More

HOUSTON / Nov 25, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7 th Annual Evercore HealthCONx Conference being held on December 3 – 5,... Read More

HOUSTON / Nov 19, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan. Dear Fellow Stockholder, Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and... Read More

HOUSTON / Nov 06, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended September 30, 2024. Recent Corporate Highlights Announced positive results from an investigator initiated double-blind... Read More

Company underscores potential benefits of low-dose interleukin-2 in Investigator-Initiated Phase 2 Alzheimer’s disease trial as presented at the recent CTAD Conference HOUSTON / Nov 01, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that, as previously... Read More

Study met Primary and Secondary Endpoints for Safety and Regulatory T cell (Treg) Cell Population Enhancement, respectively, with no off-target effects on T effector lymphocytes, providing further evidence of target engagement Exploratory Endpoints demonstrated cognitive stabilization on treatment vs. cognitive declines on placebo for LD IL-2 dosing every 4 weeks (LD IL-2 q4wks), which was associated with significant... Read More

HOUSTON / Oct 28, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2)... Read More

Majority of investors in offering were existing institutional stockholders of Coya As of September 30, 2024, the Company’s cash and cash equivalents were approximately $31.0 million HOUSTON / Oct 23, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells... Read More

Majority of investors in offering are existing institutional stockholders of Coya HOUSTON / Oct 22, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq:COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells (“Tregs”), announced today that it has entered into definitive securities purchase agreements for the... Read More

HOUSTON / Oct 08, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chairman and CEO Howard Berman, Ph.D. has been recognized as a PharmaVoice 100 winner in the category of Biotech Pathfinders . The annual list recognizes the most inspiring people in the life... Read More

HOUSTON / Sep 24, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. and Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D, will participate in a fireside chat at the Chardan 8 th Annual Genetic... Read More

A key aspect of Parkinson’s disease (PD) pathophysiology is decreased systemic regulatory T cell (Treg) function with associated neuroinflammation in the nigrostriatal pathway of the brain, including the presence of reactive astrocytes and microglia that have an initiating and progressing role in PD; Subcutaneous injection of COYA 302, an anti-inflammatory, Treg-enhancing combination biologic (comprising low dose... Read More

HOUSTON / Sep 03, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO Howard Berman, Ph.D. will present at two upcoming healthcare conferences. On September 26, 2024, Dr. Berman will participate in a panel discussion at Munsch Hardt’s 3 rd Annual Texas... Read More

Dr. Howard Berman, the founder of Coya, will transition to Executive Chair of the Board effective November 1 st , 2024 Dr. Arun Swaminathan is appointed to the Board of Directors effective immediately HOUSTON / Aug 19, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today... Read More

HOUSTON / Aug 12, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended June 30, 2024. Recent Corporate Highlights Presented updated biomarker data in late April 2024 at the 2 nd Annual... Read More

Coya had previously announced that initial topline data from this Investigator Initiated Trial (IIT) may be presented in Summer 2024. The Houston Methodist Research Institute investigators responsible for this IIT will instead be presenting the entire dataset at the CTAD24 peer reviewed medical conference in Madrid, Spain This IIT, a double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer’s... Read More

Combination of COYA 301 + GLP-1 receptor agonists (GLP-1 RA) may present a promising multi-pathway targeted approach for additive and/or synergistic anti-inflammatory functions for the potential treatment of inflammatory diseases, including neurodegenerative, autoimmune, and metabolic conditions; Data supporting these patents indicate that COYA 301 and GLP-1 RA combinations may have an additive and/or synergistic... Read More

Joint effort to leverage existing collaboration and non-dilutive grants to advance development of proprietary Treg exosome technology towards a first-in-human clinical study, continue work on validating biomarkers in a variety of neurodegenerative diseases, and explore novel synergistic drug combinations with COYA 301 (proprietary Low Dose Interleukin-2, or LD IL-2) HOUSTON / Jun 20, 2024 / Business Wire / Coya Therapeutics,... Read More

Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced Regulatory T cell (Treg) number and suppressive function in patients who were administered a combination of CTLA4-Ig Fusion... Read More

Expands on previously reported data showing the halting of disease progression in patients with ALS at six months and a corresponding reduction in inflammation, oxidative stress, and enhanced Regulatory T cell (Treg) number and suppressive function in patients who were administered a combination of CTLA4-Ig Fusion Protein and Low Dose Interleukin-2 (LD IL-2) HOUSTON / Jun 03, 2024 / Business Wire / Coya Therapeutics, Inc.... Read More

HOUSTON / May 28, 2024 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that MSCI has selected the Company’s shares for inclusion in its MSCI USA Micro Cap Index at the market close of May 31, 2024. The MSCI USA Micro Cap Index is designed to measure the performance... Read More

This investigator-initiated, double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer’s Association) evaluates the safety and tolerability, biological activity, and preliminary efficacy of LD IL-2 in 38 patients with mild-to-moderate Alzheimer’s disease (AD) over 30 weeks Previously reported data from an open-label, proof-of-concept study in eight AD patients illustrated that treatment with LD... Read More

Funds will help support the development of COYA 302 for the treatment of Frontotemporal Dementia (FTD) COYA 302’s combination therapeutic approach aligns with ADDF’s belief in combination therapy being the future of Alzheimer’s and related dementia treatments HOUSTON / May 20, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics... Read More

HOUSTON / May 09, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2024. Recent Corporate Highlights Announced successful pre-IND and Type C meetings with FDA in January 2024 to... Read More

Serum 4-Hydroxynonenal (4-HNE) levels are significantly increased in ALS patients- the higher the 4-HNE level, the faster the progression and shorter the survival; Serum 4-HNE levels are increased in bulbar vs. limb onset ALS patients and correlate with shortened survival in patients with bulbar onset ALS; Serum 4-HNE Receiver Operating Curve (ROC) Analysis demonstrates a 100% sensitivity for survival threshold of 21 months,... Read More

HOUSTON / Apr 22, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer and Chairman of the Board Howard Berman, Ph.D., and Chief Business Development Officer Arun Swaminathan, Ph.D., will participate in the Mizuho Neuroscience Summit... Read More

HOUSTON / Apr 18, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3 rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston. On May... Read More

Additional 4-HNE (4-hydroxynonenal) biomarker data to highlight the correlation of bulbar and limb onset ALS (Amyotrophic Lateral Sclerosis) to 4-HNE levels HOUSTON / Apr 08, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman... Read More

HOUSTON / Mar 19, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023. 2023 Corporate Highlights Closed IPO in January 2023 for net proceeds of $14.1 million Reached agreement... Read More

Coya’s Scientific Board Chairman Dr. Stanley Appel and Chief Medical Officer Dr. Fred Grossman to participate in discussion hosted by BTIG Analyst Tom Shrader HOUSTON / Mar 12, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D.,... Read More

4-Hydroxynonenal (4-HNE) levels strongly correlate with rate of Amyotrophic Lateral Sclerosis (ALS) disease progression and survival of patients from onset and diagnosis to death (91.7% sensitivity and 71.1% specificity) 4-HNE levels may serve as a potential surrogate biomarker to track efficacy of ALS disease modifying treatments, such as COYA 302 HOUSTON / Mar 12, 2024 / Business Wire / Coya Therapeutics, Inc . (Nasdaq:... Read More

Regulatory T cell (Treg) immunomodulatory function significantly compromised and inflammatory cytokines and chemokines significantly increased in FTD patients COYA 302, Coya’s lead investigational product, is believed to restore Treg immunomodulatory function and target the inflammatory milieu observed in neurodegenerative diseases like FTD HOUSTON / Mar 06, 2024 / Business Wire / Coya Therapeutics, Inc. (“Coya” or the... Read More

Company to present comprehensive analysis documenting pro-inflammatory cell phenotypes and Treg dysfunction in FTD patients vs. healthy controls HOUSTON / Feb 29, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Alireza Faridar, the Stanley H. Appel... Read More

Novel biomarker data in ALS patients correlates to rate of progression and survival HOUSTON / Feb 22, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, will present data on its novel... Read More

Combination biologics with LD IL-2 as a backbone may represent next-generation approaches that target complex immune pathways in neurodegenerative diseases Expansion of COYA 302 into Alzheimer’s Disease leverages synergistic mode of action and intellectual property position of the biologic combination of the Company’s proprietary low-dose interleukin-2 formulation (LD IL-2) with its proprietary CTLA4-Ig that is intended to... Read More

License from University of Nebraska Medical Center covers multiple low dose interleukin-2 (ld IL-2) combinations, including ld IL-2 + Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF); New data, viewable here, illustrate that the combination of ld IL-2 + GM-CSF results in a 4-6 fold synergistic increase in Tregs; License expands on Coya’s multi-pathway approach in identifying and combining immunomodulatory drugs with... Read More

Dr. Appel to discuss the potential of combination immunotherapy in ALS HOUSTON / Jan 29, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, has been invited to participate at the upcoming... Read More

HOUSTON / Jan 18, 2024 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces that Howard Berman, Ph.D., Chief Executive Officer and Chairman of Coya Therapeutics, Arun Swaminathan, Ph.D., Chief Business Officer, and Fred Grossman DO, President and Chief Medical Officer, have been invited to... Read More

All three conditions share common hallmark of complex inflammatory pathways underlying disease pathophysiology that involve dysfunctional regulatory T cell (Treg) biology which may limit efficacy of monotherapy approaches; COYA 302 is a proprietary biologic combination immunotherapy that targets multiple pathways which may successfully overcome the complex immune environment driving these diseases; Cash runway guidance... Read More

Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets. Pipeline programs in Small Cell Lung Cancer and Microsatellite-Stable Colorectal Cancer. Experienced team of individuals with expertise in surface proteomics and oncology from academia, biotech and pharma, led by CEO Roman Thomas . Leading biopharma executives Dieter... Read More

Coya has a clear path towards submission of the IND application to the FDA in the second quarter of 2024, with a planned initiation of a well-controlled, double-blind clinical trial of COYA 302 in patients with ALS upon acceptance of the IND HOUSTON / Jan 05, 2024 / Business Wire / Coya Therapeutics, Inc. (“Coya”), a clinical-stage biotechnology company today announced successful meetings with the U.S. Food and Drug... Read More

Secretary Ross has over 55 years’ experience as a business leader, banker, and investor and is the former Chairman and Chief Strategy Officer of WL Ross & Co. HOUSTON / Dec 20, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced... Read More

HOUSTON / Dec 13, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman. Dear Fellow Stockholders, As the year comes to a close, I want to take a moment to reflect on Coya’s... Read More

HOUSTON / Dec 12, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells (“Tregs”), announced today the closing of the sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement... Read More

HOUSTON / Dec 06, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq:COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells (“Tregs”), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a... Read More

Under the Agreement, Dr. Reddy’s will obtain commercialization rights for COYA 302 in the United States, Canada, the European Union and the United Kingdom, for patients with ALS COYA will be responsible for development, including the conduct of the Phase 2 clinical trial and for obtaining regulatory approval in the United States COYA 302 is an investigational combination biologic for subcutaneous administration, comprised of... Read More

HOUSTON / Nov 08, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update. Q3 2023 and Recent Highlights Completed... Read More

Alireza Faridar, MD (Houston Methodist and Weill Cornell Medical College) will present data from an open-label, proof-of-concept study in 8 AD patients treated with Low Dose IL-2 (LD IL-2) over a 4 month period that resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE) and no cognitive decline as observed by the AD Assessment Scale–Cognitive... Read More

The double-blind, placebo-controlled study (funded by the Gates Foundation and Alzheimer’s Association) evaluates the safety and tolerability, biological activity, biomarkers, neuroimaging, and preliminary efficacy of LD IL-2 in 38 patients with mild-to-moderate AD over 30 weeks; Previously reported data from an open-label, proof-of-concept study in 8 AD patients illustrated that treatment with LD IL-2 resulted in a... Read More

COYA 302 is an investigational and proprietary biologic combination with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages; COYA 302 is comprised of proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig, and is being developed for subcutaneous administration for the... Read More

The scientific poster highlights the role of pro-inflammatory macrophages and monocytes in reducing regulatory T cell (Treg) immunomodulatory suppressive function and the anti-inflammatory effect of Treg-enhancing therapies combined with drugs that suppress M1 pro-inflammatory activated monocytes and macrophages in ALS; COYA 302 is a dual-mechanism investigational biologic combination comprised of proprietary low dose... Read More

HOUSTON / Sep 27, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Tregs, announces that management will present at the LD Micro Investor Conference in Los Angeles, CA on October 3 at 8:00am PT. The presentation will be streamed live and available for replay at:... Read More

Supported by promising data generated during the option period, Coya has entered into an exclusive license for a next-generation EET platform to enable engineering of exosomes with potential to target epitope driven neurodegenerative, autoimmune and oncologic diseases; Exosomes are a nanometer-sized type of extracellular vesicle that can be shed from every cell in the body- Researchers have attempted to harness the exosome... Read More

Using proprietary exosome tethering modification technology, Treg derived exosomes were engineered with a surface protein, cytotoxic T lymphocyte associated protein 4 (CTLA-4) to increase selective targeting to immune cells; This patented technology requires no genetic modifications, overcomes known limitations of exosome manipulation, and enables tethering of multiple potential proteins to an exosome surface and loading of... Read More

Pathological hallmarks of ALS are characterized by alterations in inflammation and oxidative stress, with oxidative stress playing a critical role in neuronal damage. 4-hydroxy-2-nonenal (4-HNE) is a key mediator of oxidative stress in cells and tissues. Analysis of blood biomarker data from two clinical trials of Treg-enhancing therapies in patients with ALS demonstrated a strong correlation between clinical response and... Read More

Dr. Phil Campbell, Professor at Carnegie Mellon University (CMU), will present proof of concept data, on behalf of Coya, illustrating the ability to modify Regulatory T cell (Treg) exosomes to enable selective targeting of inflammatory sites while delivering cargo of interest; Technology requires no genetic modifications, overcomes prior limitations of exosome manipulation, and enables tethering of multiple potential... Read More

Mr. Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business Mr. Weinand is a seasoned business leader with over 25 years of experience leading business and strategic operations for companies including Bayer, Pfizer, Bristol Myers Squibb, Sanofi, and Otsuka HOUSTON / Aug 21, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or... Read More

HOUSTON / Aug 08, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update. Q2 2023 and Recent Highlights Presented positive... Read More

HOUSTON / Aug 03, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced that Dr. Fred Grossman, President and Chief Medical Officer, is presenting at BTIG’s Virtual Biotechnology Conference 2023, Tuesday, August 8th at 1:30 p.m. ET. This conference is being hosted by BTIG, a global... Read More

Dr. Merit Cudkowicz is the Director of the Sean M. Healey & AMG Center for ALS, Chief of Neurology at Mass General, Director and the Julieanne Dorn Professor of Neurology at Harvard Medical School. Dr. Cudkowicz’s research and clinical activities are dedicated to the study and treatment of people with ALS; she is one of the founders and past Co-Chairs of the Northeast ALS Consortium (NEALS), a group of over 134 clinical... Read More

The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of low-dose interleukin 2 (ld IL-2) in 8 patients with Alzheimer’s disease (AD). The academic study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital. The additional clinical data show a significant decrease in biomarker levels known to be associated with neuroinflammation in... Read More

Dr. Grossman brings over 20 years of drug development expertise having held senior executive leadership positions in large and small pharmaceutical companies leading the development and FDA approval of numerous multi-billion dollar blockbuster drugs addressing significant unmet medical needs particularly across CNS disorders. Dr. Grossman held executive positions at Eli Lilly, Johnson & Johnson, Bristol Myers Squibb, and... Read More

The academic proof-of-concept open-label study evaluated the biological activity, cytokine and chemokine blood biomarkers, safety, and preliminary efficacy of low-dose interleukin-2 (ld IL-2) in 8 patients with mild-to-moderate AD. The study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital. Coya’s investigational low-dose interleukin-2 (ld IL-2) for subcutaneous administration has been designed to... Read More

Enters Licensing Agreement with UNeMed Corporation (UNeMed), the Technology Transfer Office of University of Nebraska Medical Center Abundant evidence indicates that high levels of inflammation and decreased levels of Regulatory T cells (Tregs) lead to an increased oxidative state in PD, which play a major role in disease progression and possibly etiology COYA 301 is a low-dose-IL-2 (ld IL-2) formulation for subcutaneous... Read More

Dr. Frazier brings over 20 years of strong regulatory expertise since her tenure at the FDA followed by a successful career in the pharmaceutical industry. Dr. Frazier spent 7 years at the FDA, where she was a team lead reviewing over 60 new molecular entities, overseeing multiple biologic license applications, including the first anti-angiogenic monoclonal antibody approved for cancer therapy. In turn, she was recognized... Read More

HOUSTON / Jun 12, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman. Dear Fellow Stockholders, It’s hard to believe it’s now 6 months since our IPO closed on January 3 rd of... Read More

Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of... Read More

Dr. Guillaume Dorothée, Ph.D., is a tenured research director and team head in neuroimmunology at the French National Institute of Health and Medical Research (INSERM) in Paris He is one of the world’s leading experts on the role that the immune system and peripheral-central immune crosstalk play in the pathophysiology of AD His team was the first to illustrate the beneficial role of Regulatory T cells (Tregs) in AD and the... Read More

Coya previously announced results from an open-label study of COYA 301 in 8 patients with Alzheimer’s disease (AD) that resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE). Coya to present on additional blood biomarker data for pro- inflammatory cytokines Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta... Read More

The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of COYA 301 in 8 patients with Alzheimer’s disease (AD). The investigator-initiated study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital. COYA 301 is Coya’s investigational low-dose interleukin-2 (IL-2) for subcutaneous administration. COYA 301 has been designed to enhance... Read More

HOUSTON / May 10, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the first quarter ended March 31, 2023, and provided a clinical and business update. Q1 2023 and Recent Highlights (Unaudited) Announced... Read More

HOUSTON / May 09, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologic immunotherapies intended to enhance function of Regulatory T Cells (Tregs) function while resolving toxic inflammation, today announced management will present at the Sidoti Virtual Investor Conference Thursday May 11 at 2:30pm ET. The presentation can be... Read More

The proof-of-concept open-label study evaluated the safety and tolerability, regulatory T cell (Treg) function, blood biomarkers, and preliminary efficacy of COYA 301 in eight patients with mild-to-moderate AD. The academic study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital. COYA 301 is Coya’s investigational low-dose interleukin-2 (IL-2) for subcutaneous administration. COYA 301 has been... Read More

HOUSTON / Mar 29, 2023 / Business Wire / Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells (Tregs) function, today announced its financial results for fiscal year ended December 31, 2022, and provided a clinical and business update. FY 2022 and Early 2023 Highlights In March 2023,... Read More

Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two... Read More

HOUSTON / Mar 23, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced management will present at the Virtual Investor Summit on Wednesday, March 29, 2023 at 11:00am ET. Investors can view the webcast here . Management... Read More

Coya Therapeutics, Inc. (NASDAQ: COYA) recently reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to significantly ameliorate disease progression (stopping progression in all patients at 24 weeks with minimal decline at 48 weeks.) This was in a patient cohort who was declining prior to entry into the study. Four ALS patients with a mean... Read More

HOUSTON / Mar 21, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced it will host a conference call to present positive clinical data announced earlier today , of Coya’s proprietary investigational biologic... Read More

HOUSTON / Mar 21, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to ameliorate... Read More

HOUSTON / Mar 20, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr.... Read More

HOUSTON / Mar 09, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced it will host a conference call to present clinical data of Coya’s proprietary investigational biologic combination, COYA 302, in patients with... Read More

Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary investigational biologic combination at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, to be held in-person and virtually from March 19 to March 22, 2023. The proof-of-concept open-label clinical study is the... Read More

Houston, Texas-based Coya Therapeutics Inc. (NASDAQ: COYA) has just taken a giant leap in making effective proprietary treatments focused on certain neurodegenerative and autoimmune diseases available to more patients, as it announced the expansion of its exclusive worldwide rights for the development and commercialization of COYA 301 — the company’s low-dose IL-2 subcutaneous administration product candidate. For industry... Read More

HOUSTON / Feb 15, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced expansion of its exclusive worldwide rights for the development and commercialization of COYA 301, the Company’s low-dose IL-2 subcutaneous... Read More

COYA 301 (biologic monotherapy) clinical and biomarkers data in patients with Alzheimer’s disease (AD) to be presented in 1H 2023 and 2H 2023 COYA 302 (biologics combination therapy) clinical and biomarkers data in patients with Amyotrophic Lateral Sclerosis (ALS) to be presented in Q1 2023 HOUSTON / Feb 02, 2023 / Business Wire / Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage... Read More

Administration of expanded human Tregs with amplified immunomodulatory function suppressed neuroinflammation and alleviated AD pathology in a mice model of AD. Expanded human Tregs reduced amyloid burden and downregulated neuroinflammatory markers in the brain including pro-inflammatory cytokines, complement cascade, toll like receptors, and microglia. Data provide preclinical support for Treg enhancing therapies as a... Read More